Evaluation of basal estradiol levels in assisted reproductive technology cycles
|
|
- Easter O’Neal’
- 5 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY VOL. 74, NO. 3, SEPTEMBER 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Evaluation of basal estradiol levels in assisted reproductive technology cycles John L. Frattarelli, M.D., a Paul A. Bergh, M.D., b,c Michael R. Drews, M.D., b,c Fady I. Sharara, M.D., d and Richard T. Scott, Jr., M.D. b,c Combined Federal Program for Reproductive Endocrinology at Walter Reed Army Medical Center, National Naval Medical Center, Uniformed Services University for the Health Sciences, and National Institutes of Health, Bethesda, Maryland; The Institute for Reproductive Medicine and Science of Saint Barnabas Medical Center, Livingston, New Jersey; Reproductive Medicine Associates of New Jersey, Morristown, New Jersey; and University of Maryland, Baltimore, Maryland Received December 13, 1999; revised and accepted March 21, Reprint requests and present address: John L. Frattarelli, M.D., Department of Obstetrics and Gynecology, Tripler Army Medical Center, 1 Jarrett White Road, Tripler AMC, HI (FAX: ; jfratt@yahoo.com). a Combined Federal Program for Reproductive Endocrinology at WRAMC, NNMC, USUHS, and NIH. b The Institute for Reproductive Medicine and Science of Saint Barnabas Medical Center. c Current address: Reproductive Medicine Associates of New Jersey. d Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland. The opinions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense /00/$20.00 PII S (00) Objective: To determine if basal E 2 screening increases the diagnostic accuracy of basal FSH screening and to determine whether basal E 2 levels correlate with outcome in ART cycles. Design: Retrospective. Setting: Tertiary care center. Patient(s): Two thousand six hundred thirty-four infertility patients. Intervention(s): Cycle outcome was evaluated after grouping patients by basal E 2 levels beginning at 20 pg/ml and extending to 100 pg/ml at 10 pg/ml increments. Main Outcome Measure(s): Retrieved oocytes, pregnancy rate, and cancellation rate. Result(s): Cancellation rates were significantly increased in patients with basal E 2 levels of 20 pg/ml or 80 pg/ml. Basal E 2 levels neither predicted pregnancy outcome nor correlated with ovarian response in those patients not canceled. Conclusion(s): Patients with basal E 2 levels of 20 pg/ml or 80 pg/ml had an increased risk for cancellation. Basal E 2 was predictive of stimulation parameters in patients 40 years or older. For those patients who proceeded to retrieval, there were no differences in pregnancy or delivery rates relative to basal E 2 levels. This suggests that irrespective of basal E 2 levels patients who produce more than three maturing follicles in response to stimulation have adequate ovarian reserve as evidenced by their pregnancy rates. (Fertil Steril 2000;74: by American Society for Reproductive Medicine.) Key Words: Assisted reproductive technology, in vitro fertilization, estradiol, follicle-stimulating hormone, ovarian reserve, pregnancy rates, cancellation rates, review The evaluation of ovarian reserve has been the focus of much clinical research over the last several years (1 15). A number of tests have been suggested to prognosticate ovarian responsiveness to exogenous gonadotropin stimulation, the quality of the oocytes retrieved, and the subsequent implantation and pregnancy rates (1 13). Most of these tests are based on circulating FSH levels in the basal state (basal day 3 FSH levels) or after treatment with the antiestrogen clomiphene citrate (the clomiphene citrate challenge test). The prognostic value of these tests has been clearly shown by a number of investigators in a wide variety of settings (1 13). Despite their increasing acceptance in clinical practice, the tests continue to have a variety of significant shortcomings. The principal limitation is the lack of predictive value of a normal result. Although the predictive value of an abnormal result is high with pregnancy rates of 5% (in many cases 1%), the predictive value of a normal result is limited because many patients with poor gonadotropin responsiveness and low-quality oocytes and embryos have normal screening results (11). Thus, the available tests for diminished ovarian reserve are specific but not sensitive. The lack of sensitivity has led a number of investigators to evaluate other tests to identify those patients whose ovarian reserve is insufficient to allow them to conceive (16 21). Recently, serum basal E 2 has been evaluated (17 20). This particular hormone is most attractive 518
2 because it is a direct product of the ovary, which may be assayed in virtually any endocrine laboratory. It has been postulated that the elevation in basal E 2 levels may suppress otherwise elevated FSH levels into the normal range, thus masking what might have been an abnormal test result. Three groups of investigators described decreases in clinical outcomes for patients with elevated basal E 2 levels (17 19). The purposes of this study were to evaluate the predictive value of basal E 2 levels in assisted reproductive technology (ART) cycles based on a large cohort of patients, to compare basal E 2 levels with clinical outcomes of pregnancy and cancellation rates, and to determine if specific basal E 2 levels predicted clinical response. MATERIALS AND METHODS Population All patients who initiated IVF cycles in our ART program between June 1996 and November 1998 (n 3,365) and whose basal day 3 FSH and E 2 levels were determined in our laboratory were considered for inclusion in the study. Patients were included independent of their age, diagnoses, or reproductive history. For patients (n 482) undergoing multiple cycles (n 731), only their first cycle was included for evaluation. Patients (n 21) with elevated FSH levels ( 14 miu/ml) were excluded from further analysis because their poor prognosis was previously established (7). Likewise, patients (n 137) who had ovarian screening at an outside laboratory were excluded; remaining were 2,476 patients who met the inclusion criteria. Institutional Review Board approval from Saint Barnabas Medical Center was obtained. Experimental Design All day 3 basal FSH, LH, and E 2 measurements were made during a spontaneous cycle within 6 months before undergoing ART. Patients underwent stimulation with a GnRH analogue (GnRH-a) down-regulation followed by stimulation with exogenous gonadotropins or concomitant initiation of GnRH-a and exogenous gonadotropins ( flare cycles), as previously described (21, 22). Specifically, those patients (n 260) who showed poor follicular response in prior ART cycles and those patients thought to be at risk for poor response based on their age and hormone values were started on a follicular phase GnRH-a flare protocol. Retrieval, transfer, and all andrological and embryological procedures were completed as previously described (23, 24). Biochemical pregnancies were defined as having a positive pregnancy test on luteal day 16 with a rising titer confirmed by a second hcg level but with loss of the pregnancy before the development of sonographic evidence of the pregnancy. Clinical pregnancy was defined as a pregnancy documented by sonographic confirmation of an intrauterine pregnancy. Ongoing or delivered pregnancies were defined as gestations that progressed beyond 13 weeks of gestational age that were proceeding normally or that had been delivered. Cycles were canceled for failing to produce three or more expanding follicles and/or failure to respond to gonadotropins with an adequate E 2 response of 500 pg/ml. Laboratory Assays The LH, FSH, and E 2 assays were all performed with the Immulite immunoassay system (Diagnostic Products Corporation, Los Angeles, CA). The interassay and intraassay coefficients of variation were 6.6% and 5.4% for FSH, 5.8% and 4.6% for LH, and 5.4% and 4.4% for E 2, respectively. Statistical Analysis Patients with normal FSH levels were grouped by basal E 2 levels between 20 pg/ml and 100 pg/ml at 10 pg/ml increments. Cancellation, biochemical pregnancy, clinical pregnancy, and ongoing or delivery rates were calculated for each increment. Pregnancy and cancellation rates above each threshold were evaluated with receiver operating characteristic (ROC) curves to determine if there were any obvious break points above which there was an obvious change in these rates. Contingency table analysis was then used to assess the pregnancy and cancellation rates above and below the selected threshold value. Spearman s correlation coefficients were calculated to measure the strength of the association between the ovarian response and stimulation parameters. The predictive accuracy of these variables was compared by simple linear regressions where the ovarian response was represented by the number of oocytes retrieved. Multilinear regression was then used to determine the best predictors of outcome. A Kruskal-Wallis one-way analysis of variance was used to compare basal E 2 levels, patient age, day 3 FSH levels, and day 3 LH levels within each of the pregnancy groups and the cancellation group to determine if there were differences in the population means. For pairwise multiple comparison, Dunn s method was used. A Mann-Whitney rank sum test was used to compare means between two groups. An alpha error of 0.05 was considered significant for all comparisons. All data are reported as means with their associated standard deviations. RESULTS A total of 3,365 ART cycles were initiated during the study interval. There were 482 patients who underwent a total of 731 repeat cycles. These 731 repeat cycles were excluded from our analysis. Ovarian reserve screening was determined in our laboratory in 2,497 of the remaining 2,634 patients. Of these, 2,476 were performed in women with normal basal FSH levels ( 14 miu/ml). This group (n 2,476) constituted the population for this study. Cancellation at any time after initiating gonadotropins occurred in 343 patients, and 2,133 patients went to oocyte retrieval. There FERTILITY & STERILITY 519
3 TABLE 1 Demographics and stimulation characteristics for the 2,476 ART patients in the study group. Variable No. Age Basal FSH level Basal E 2 level Basal LH level Peak E 2 level No. of oocytes No. of days of gonadotropins No. of ampules of gonadotropins Total population 2, ,496 1, Canceled cycles Not pregnant ,453 1, Total pregnancies 1, ,517 1, Ongoing/delivered 1, a a 2,530 1, a Clinical loss ,543 1, Biochemical pregnancies ,394 1, Note: Values are means SD. a Significantly different from the not pregnant, clinical pregnancy loss, and biochemical pregnancy groups using a Kruskal-Wallis one-way analysis of variance (P.01). were 1,421 pregnancies for a crude pregnancy rate of 66.6% per retrieval. Of these, 141 were biochemical (9.9% of pregnancies) and 149 were clinical losses (10.5% of pregnancies). There were a total of 1,131 ongoing pregnancies and deliveries (79.6% of pregnancies; 53% per retrieval). Table 1 displays the demographics and stimulation characteristics for the study group. With use of a Kruskal-Wallis one-way analysis of variance, there were no statistically significant differences in the mean basal E 2 levels (P.07) between those women who did not conceive ( pg/ml), those who had biochemical pregnancies ( pg/ml), those who had clinical losses ( pg/ml), or those with ongoing pregnancies or deliveries ( pg/ml). Similarly, there were no statistically significant differences in basal day 3 FSH levels (P.77), stimulation quality as evidenced by peak E 2 levels (P.70), days of stimulation (P.21), or ampules of gonadotropins administered (P.14). Patients with ongoing pregnancies or deliveries had significantly more oocytes retrieved ( ) than did patients not conceiving ( ), patients experiencing a biochemical loss ( ), and patients experiencing a clinical loss ( ) (P.01). Patients with ongoing pregnancies or deliveries were significantly younger ( ) than patients not conceiving ( ), patients experiencing a biochemical loss ( ), and patients experiencing a clinical loss ( ) (P.01). Likewise, patients with ongoing pregnancies or deliveries had higher day 3 LH levels ( miu/ml) than patients not conceiving ( miu/ml), patients experiencing a biochemical loss ( miu/ml), and patients experiencing a clinical loss ( miu/ml) (P.01) (Table 1). When the stimulation characteristics of peak E 2 and number of oocytes retrieved were evaluated throughout the full range of E 2 values with efficiency curves, no obvious difference was seen until the groups were subdivided by age. The only difference noted was in the patients 40 years. In these patients, an E 2 level of 80 pg/ml was predictive of a poor response producing a lower number of oocytes ( vs ) (P.01) and a lower peak E 2 level (2,278 1,157 vs. 1, ) (P.01). In this group of patients, the number of days of stimulation ( vs ) and ampules of gonadotropins used ( vs ) were not altered significantly by an elevation in E 2 level. The overall pregnancy and cancellation rates relative to basal E 2 measurements are shown in Figure 1. Contingency FIGURE 1 Overall pregnancy and cancellation rates for each basal E 2 range. *Contingency table analysis, P Frattarelli et al. Basal estradiol levels in ART cycles Vol. 74, No. 3, September 2000
4 TABLE 2 Distribution of ART cycles and their outcome relative to basal E 2 levels among the patient population. Basal E 2 level No. of retrievals No. of total pregnancies (%) No. of ongoing/ delivered (%) No. of clinical losses (%) No. of biochemical pregnancies (%) No. of canceled cycles (%) (62.5) 139 (52.1) 16 (9.6) 12 (7.2) 83 (23.7) a (69.4) 207 (52.4) 32 (11.7) 32 (11.7) 65 (14.1) (67.6) 275 (52.4) 48 (13.5) 32 (9.0) 77 (12.8) (65.1) 240 (53.9) 24 (8.3) 27 (9.3) 44 (9.0) (69.0) 128 (53.6) 16 (9.7) 22 (13.3) 26 (9.8) (63.2) 73 (54.9) 4 (4.8) 7 (8.3) 18 (11.9) (69.5) 33 (55.9) 4 (9.8) 4 (9.8) 8 (11.9) (61.5) 14 (53.8) 1 (5.8) 2 (11.8) 6 (18.8) a (90.0) 8 (80.0) 1 (11.1) 0 (0) 4 (28.6) (58.8) 14 (41.2) 3 (15.0) 3 (15.0) 12 (26.1) Total 2,133 1,421 (66.6) 1,131 (53.0) 149 (10.5) 141 (9.9) 343 (13.9) Note: Values represent the total number of patients per group with percentages in parentheses. a Represents a break point in the data (P.01). table analyses detected no differences in overall pregnancy rates for any basal E 2 level (Table 2). The ROC curves for overall pregnancy rates or pregnancy loss rates revealed no obvious differences throughout the full range of values. Similar evaluations for the subset of patients 35 years of age, years of age, and those 40 years of age revealed no differences in pregnancy rates or outcome. Thus, basal E 2 levels did not correlate with pregnancy rates or cycle outcome. The efficiency curves for cancellation rates suggested an increased risk for patients whose basal E 2 level was 20 ng/ml or 80 pg/ml. Contingency table analyses confirmed that the risk for cancellation was increased in patients with basal E 2 levels of 20 ng/ml (P.01, odds ratio [OR] 2.23, 95% confidence interval [CI] ) or of 80 pg/ml (P.01, OR 2.02, 95% CI ) (Table 2). For E 2 levels of 20 ng/ml, the positive predictive value was 23.7%, and the negative predictive value was 87.8%, whereas for E 2 levels of 80 pg/ml the positive predictive value was 23.9%, and the negative predictive value was 86.5%. Evaluating the age-related risk of cancellation offered no additional statistical benefit. A linear regression analysis was used to determine the correlation of patient age, basal FSH, basal LH, and basal E 2 levels with ovarian response (i.e., number of oocytes retrieved). Patient age (r 0.36, P.01) and basal FSH level (r 0.82, P.01) revealed a significant negative linear correlation with ovarian response. Basal LH level showed a positive linear correlation with ovarian response (r.37, P.01). Basal E 2 level did not correlate with ovarian response (P.59). Likewise, a multiple linear regression analysis revealed that basal FSH level, basal LH level, and patient s age were the best predictors of ovarian response. With use of a Mann-Whitney rank sum test, the canceled patients were compared with those patients not canceled. Canceled patients had significantly higher basal E 2 levels ( pg/ml) than noncanceled patients ( pg/ml) (P.01). Likewise, canceled patients were significantly older (P.01) and had lower basal FSH (P.03) and LH levels (P.01). Similar evaluations were performed on subsets of patients who were canceled vs. not canceled, subdividing the patients into the following groups: 35 years of age, years of age, and 40 years of age. Basal serum LH levels were significantly lower in all of the canceled patients (P.01). After subdividing by age, basal serum FSH levels did not statistically significantly differ in canceled vs. noncanceled patients. It is of interest that the basal E 2 levels for canceled patients were significantly lower in the group 35 years of age (P.01) and significantly higher in the two groups older than 35 years of age (P.01) (Table 3). DISCUSSION The data in this study indicated that undetectable or elevated E 2 levels on cycle day 3 correlate with higher cancellation rates during ART cycles. However, if patients continued to retrieval, there was no difference in the pregnancy or delivery rates. The E 2 levels did not correlate with stimulation parameters except in the patients 40 years and older, where a lower peak E 2 and fewer oocytes were seen with an E 2 level of 80 pg/ml. Ours is the first study that documented a detrimental effect of a low E 2 value on patients undergoing ART. We found that in the 350 patients with an E 2 level of 20 pg/ml there was a significant increase in cancellation rates. The theoretical principle that supports basal E 2 screening FERTILITY & STERILITY 521
5 TABLE 3 Canceled patients vs. noncanceled patients: comparison of the overall patient population and the three age subsets ( 35, 35 39, 40 years). No. Age (y) FSH LH E 2 Canceled (all) Not canceled (all) 2, P value 0.01 a 0.03 a 0.01 a 0.01 a Canceled ( 35 years) Not canceled ( 35 years) P value a 0.01 a Canceled ( y) Not canceled ( y) P value 0.01 a a 0.01 a Canceled ( 40 y) Not canceled ( 40 y) P value a 0.55 Note: Values are means SD. a Values represent statistically significant difference (P.05) using a Mann Whitney rank sum test. is the ability to detect patients with shortened follicular phases who may have progressed far enough into their follicular phases to invalidate the evaluation of their basal FSH levels. This might be thought of in simpler terms as a suppression of an otherwise abnormal FSH level into the normal range by elevated E 2 levels. However, this suppression is more likely the impact of a number of secretory products and not E 2 alone. Evaluation of other secretory products of the ovary are also currently being evaluated. Recent reports suggest that measurement of dimeric inhibin levels may add additional information to the more traditional forms of ovarian reserve screening (16). Basal FSH screening is only valid during a relatively narrow window within a given menstrual cycle. It has been shown that the age-related elevation in FSH levels occurs exclusively in the early follicular phase and that any differences become undetectable by the mid to late follicular phase (25). This is likely due to the increased secretion of E 2 and a variety of ovarian peptides whose effects are integrated to lower FSH levels. For these reasons, there has been a long-standing concern that the sensitivity of FSH screening might not be valid in patients with E 2 levels that appear to be beyond those typically seen on day 3. Consistent with that concern is the fact that patients with elevated progesterone levels on day 10 during the clomiphene citrate challenge test have diminished ovarian reserve even if their FSH levels are normal (26). This evidence of luteinization indicates a markedly shortened follicular phase, which is one of the hallmarks of reproductive aging. These patients do uniformly poorly despite having FSH values in the normal range. Table 4 summarizes the four prior publications detailing the value of basal E 2 measurements as a component of ovarian reserve screening. The first, by Licciardi et al. (17), described a decrease in oocyte number and pregnancy rates with increasing E 2 levels, which were measured during an ART cycle not using a GnRH-a. However, the data as presented in the manuscript, indicated that once the investigators controlled for elevated FSH levels there was no statistically significant difference in pregnancy rates. The data by Licciardi et al. (17) seemed to indicate that basal E 2 screening did not add significant information beyond that obtained with basal FSH screening alone. Smotrich et al. (18) found a significant decline in pregnancy rates and increase in cancellation rates among 292 patient cycles with rising basal E 2 levels, which were measured in a cycle proximate to the stimulation cycle. This correlation persisted even after controlling for basal FSH status and patient age. Smotrich et al. (18) described a clinically meaningful threshold level at approximately 80 pg/ml based on 18 patients (27 cycles) with estradiol levels above this threshold. Evers et al. (19) measured E 2 levels on cycle day 3 in a spontaneous cycle before beginning GnRH-a; they evaluated 231 cycles and found an E 2 threshold level of 60 pg/ml where they obtained no pregnancies. Likewise, in their 16 patients with E 2 levels of 60 pg/ml, Evers et al. (19) also found a significantly lower number of oocytes retrieved. In contrast to the three above-mentioned studies, Vazquez et al. (20) used a study population of 248 patient cycles in which E 2 levels were evaluated on cycle day 2 with GnRH-a and gonadotropins added thereafter; they concluded that E 2 levels below the age of 35 years were not helpful. Common themes in the previous publications evaluating 522 Frattarelli et al. Basal estradiol levels in ART cycles Vol. 74, No. 3, September 2000
6 TABLE 4 Comparison of previously published studies evaluating the prognostic value of E 2 in patients undergoing ART cycles to the current study. Study ART cycles a E 2 threshold ART cycles above threshold b Results Licciardi et al., Decreased pregnancy rates Decreased oocyte number No pregnancies Smotrich et al., Increased cancellation rates, decreased pregnancy rates No pregnancies Evers et al., Decreased oocyte number, increased cancellation rates, and no pregnancies Vazquez et al., ? Decreased implantation and pregnancy rates only in patients older than 35 years Frattarelli et al., , Increased cancellation rates Increased cancellation rates a Total number of ART cycles evaluated in the published article. b Total number of ART cycles above the published threshold E 2 level. basal E 2 levels and ovarian response in ART were small patient groups and E 2 values not based on statistical cutoff points (Table 4). In the article by Licciardi et al. (17), 30 patients had E 2 levels of 75 pg/ml, and none of the patients became pregnant. Evers et al. (19) had 16 patients with E 2 levels of 60 pg/ml, which resulted in no pregnancies. Likewise, Smotrich et al. (18) had 27 patient cycles with E 2 levels of 80 pg/ml resulting in 3 pregnancies and 15 patient cycles with E 2 levels of 100 pg/ml, which resulted in no pregnancies. In contrast, we had 92 patients with basal E 2 levels of 80 pg/ml, resulting in 46 pregnancies (65.7%) and 22 cancellations (33.9%) (Table 2, Fig. 1). Furthermore, we had 46 patients with basal E 2 levels of 100 pg/ml, resulting in 20 pregnancies (58.8%) and 12 cancellations (26.1%). With a sample size of 2,476 patients, the current study did detect a difference in reproductive performance in patients with undetectable or elevated E 2 levels on cycle day 3. These patients were more likely to respond poorly to gonadotropin stimulation, producing three or fewer follicles. However, among most patients who did respond well enough to stimulation to proceed to retrieval, the current study could not identify a basal E 2 value at which the probability for pregnancy declined. These data suggest that some patients with normal ovarian reserve will occasionally have a delayed or an accelerated cycle with either low or midfollicular levels of E 2 being present by day 3. Thus, the population of patients who truly have diminished ovarian reserve may be diluted by others having an occasional accelerated cycle. This is consistent with the data found in the original description of basal FSH screening when E 2 levels did not seem to add significantly to the test. In our observations, we noted some interesting results (Table 3). First, after excluding all patients with elevated day 3 FSH levels, the patients who were canceled had a significantly lower basal FSH level. Although not statistically significant, this finding persisted when the patients were subdivided by age. Second, the canceled patients had significantly higher basal E 2 levels. However, when subdivided by age, the canceled patients 35 years of age had a significantly lower basal E 2 level, whereas the canceled patients 35 years of age had higher basal E 2 levels than those patients not canceled. This finding could suggest that diminished ovarian reserve in younger patients may be manifested by a delayed E 2 response, whereas in older patients an accelerated response is seen. As with any retrospective study, introduction of bias into the study must be evaluated. We tried to minimize bias by including all patients meeting our inclusion criteria regardless of diagnosis and age. Subsequently, we statistically evaluated each of the subgroups by age. Theoretically, including patients with the diagnosis of PCOS could bias our results by increasing our total number of oocytes retrieved and elevating the pregnancy rate in those patients with an elevated E 2. However, only 3% of our patients had polycystic ovary syndrome (PCOS) as their primary diagnosis. When those patients with PCOS were removed from the analysis, there was no change in any of our statistical values. Therefore, we retained the patients with PCOS in our analysis. The inclusion of patients undergoing a microdose flare protocol could also have introduced bias into our data. These 260 patients on the microdose protocol were not statistically older than the remaining population of 2,216. Because by removing these 260 patients from the data analysis no change in the statistical values occurred, these patients also were retained in the data analysis. In summary, the addition of basal E 2 measurements to ovarian reserve screening may allow clinicians to identify patients who are at increased risk for cancellation. In those FERTILITY & STERILITY 523
7 patients 40 years, an elevated E 2 level of 80 pg/ml correlated with poor stimulation outcome as evidenced by a lower peak E 2 level and fewer oocytes. Nevertheless, most patients stimulated adequately, proceeded to retrieval, and then achieved pregnancy rates commensurate with their age. Patients with basal E 2 levels that are undetectable or above the normal early follicular range should not be counseled that they have diminished ovarian reserve. Although cycle outcome was poorer, elevated basal E 2 levels would not seem to be a reason to cancel or postpone a patient s stimulation cycles. References 1. Scott RT, Hofmann GE, Oehninger S, Muasher SJ. Intercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization. Fertil Steril 1990;53: Scott RT, Toner JF, Muasher SJ, Oehninger SC, Robinson S, Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989;51: Navot D, Rosenwaks Z, Margalioth EJ. Prognostic assessment of female fecundity. Lancet 1987;2: Hofmann GE, Sosnowski J, Scott RT, Thie J. Efficacy of selection criteria for ovarian reserve screening using the clomiphene citrate challenge test in a tertiary fertility center population. Fertil Steril 1996;66: Loumaye E, Billion JM, Mine JM, Psalit I, Pensis M, Thomas K. Prediction of individual response to controlled ovarian hyperstimulation by means of a clomiphene citrate challenge test. Fertil Steril 1990;53: Pearlstone AC, Fournet N, Gambone JC, Pang SC, Buyalos RP. Ovulation induction in women age 40 and older: the importance of basal follicle-stimulating hormone level and chronological age. Fertil Steril 1992;58: Scott RT, Toner JF, Muasher SJ, Oehninger SC, Robinson S, Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989;51: Scott RT, Leonardi MR, Hofmann GE, Illions EH, Neal GS, Navot D. A prospective evaluation of clomiphene citrate challenge test screening in the general infertility population. Obstet Gynecol 1993;82: Scott RT, Dellinger CL, Leonardi MR, Illions EH, Hofmann GE, Navot D. Evaluation of the significance of a poor estradiol response during the clomiphene citrate challenge test. Fertil Steril 1993;60: Scott RT, Opsahl MS, Leonardi MR, Neal GS, Illions EH, Navot D. Life table analysis of pregnancy rates in a general infertility population relative to ovarian reserve and patient age. Hum Reprod 1995;10: Scott RT, Hofmann GE. Prognostic assessment of ovarian reserve. Fertil Steril 1995;63: Tanbo T, Dale PO, Abyhom T, Stokke KT. Follicle-stimulating hormone as a prognostic indicator in clomiphene citrate/human menopausal gonadotrophin-stimulated cycles for in vitro fertilization. Hum Reprod 1989;6: Toner JP, Philput CB, Jones GS, Muasher SJ. Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991;55: Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab 1996;81: Klein NA, Battaglia DE, Clifton DK, Bremner WJ, Soules MR. The gonadotropin secretion pattern in normal women of advanced reproductive age in relation to the monotropic FSH rise. J Soc Gynecol Invest 1996;3: Seifer DB, Gardiner AC, Lambert-Messerlian G, Schneyer AL. Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. J Clin Endocrinol Metab 1996;81: Licciardi FL, Liu HC, Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 1995; 64: Smotrich DB, Widra EA, Gindoff PR, Levy MJ, Hall JL, Stillman RJ. Prognostic value of day 3 estradiol on in vitro fertilization outcome. Fertil Steril 1995;64: Evers JLH, Slaats P, Land JA, Dumoulin JCM, Dunselman GAJ. Elevated levels of basal estradiol-17 predict poor response in patients with normal basal levels of follicle-stimulating hormone undergoing in vitro fertilization. Fertil Steril 1998;69: Vazquez ME, Verez JR, Stern JJ, Najar AG, Asch RH. Elevated basal estradiol levels have no negative prognosis in young women undergoing ART cycles. Gynecol Endocrinol 1998;12: Droesch K, Muasher ST, Brzyski R, Jones SG, Simonetti S, Liu HCH, et al. Value of suppression with a GnRH-a prior to gonadotropin stimulation for in vitro fertilization. Fertil Steril 1989;51: Scott RT, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril 1994;61: Cohen J, Alikani M, Trowbridge J, Rosenwaks Z. Implantation enhancement by selective assisted hatching using zona drilling of embryos with poor prognosis. Hum Reprod 1992;7: Schoolcraft WB, Schlenker T, Gee M, Jones GS, Jones HW. Efficacy of assisted hatching in poor prognosis IVF candidates. Fertil Steril 1994; 62: Lenton EA, Sexton L, Lee S, Cooke ID. Progressive changes in LH and FSH and LH:FSH ratio in women throughout reproductive life. Maturitas 1988;10: Hofmann GE, Scott RT Jr, Horowitz GM, Thie J, Navot D. Evaluation of the reproductive performance of women with elevated day 10 progesterone levels during ovarian reserve screening. Fertil Steril 1995;63: Frattarelli et al. Basal estradiol levels in ART cycles Vol. 74, No. 3, September 2000
IN VITRO FERTILIZATION
FERTILITY AND STERILITY VOL. 82, NO. 4, OCTOBER 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. IN VITRO FERTILIZATION Prognostic
More informationin vitro fertilization
FERTILITY AND STERILITY VOL 69, NO. 6, JUNE 1998 Copyright (#1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Elevated levels of basal
More informationElena H. Yanushpolsky, M.D., a Shelley Hurwitz, Ph.D., b Eugene Tikh, B.S., c and Catherine Racowsky, Ph.D. a
FERTILITY AND STERILITY VOL. 80, NO. 1, JULY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Predictive usefulness of cycle
More informationPrognostic value of day 3 estradiol on in vitro fertilization outcome*
FERTILITY AND STERILITY Vol. 64, No.6, December 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Prognostic value of day 3 estradiol on in vitro fertilization
More informationTimur Giirgan, M.D.* Bulent Urman, M.D. Hakan Yarali, M.D. Hakan E. Duran, M.D.
FERTILITY AND STEFULI~ Vol. 68, No. 3, September 1997 Copyright 1997 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Published by Elsevier Science Inc. Follicle-stimulating
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationCigarette smoking accelerates the development of diminished ovarian reserve as evidenced by the clomiphene citrate challenge test*
FERTILITY AND STERILITY Copyright @ 1994 The American Fertility Society Printed on acid-free paper in U. s. A. Cigarette smoking accelerates the development of diminished ovarian reserve as evidenced by
More informationIntercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization*
FERTILITY AND STERILITY Copyright C> 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Inter variability of day 3 follicle-stimulating hormone levels and its effect on stimulation
More informationArticle Evaluation of functional ovarian reserve in 60 patients
RBMOnline - Vol 7. No 2. 200 204 Reproductive BioMedicine Online; www.rbmonline.com/article/846 on web 12 June 2003 Article Evaluation of functional ovarian reserve in 60 patients Dr Giuseppe Loverro Giuseppe
More informationEstradiol Level on Day 2 and Day of Trigger: A Potential Predictor of the IVF-ET Success
DOI 10.1007/s13224-014-0515-6 ORIGINAL ARTICLE Estradiol Level on Day 2 and Day of Trigger: A Potential Predictor of the IVF-ET Success Prasad Sudha Kumar Yogesh Singhal Megha Sharma Shashi Received: 27
More informationChanges in measured endometrial thickness predict in vitro fertilization success
Changes in measured endometrial thickness predict in vitro fertilization success Grant D. E. McWilliams, D.O., a and John L. Frattarelli, M.D. b a Tripler Army Medical Center, Honolulu, Hawaii; and b Reproductive
More informationCorrelation of the Day 3 FSH/LH Ratio and LH Concentration in Predicting IVF Outcome
Original Article Correlation of the Day 3 FSH/LH Ratio and LH Concentration in Predicting IVF Outcome Sudha Prasad 1*, Teena Gupta 1, Aabha Divya 2 1- IVF and Reproductive Biology Centre, Department of
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationOvulation induction in women age 40 and older: the importance of basal follicle-stimulating hormone level and chronological age*
FERTILITY AND STERILITY Vol. 58, No.4, October 1992 Copyright It! 1992 The American Fertility Society Printed on acid-free paper in U. S.A. Ovulation induction in women age 40 and older: the importance
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationIN VITRO FERTILIZATION
FERTILITY AND STERILITY VOL. 79, NO. 1, JANUARY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. IN VITRO FERTILIZATION
More informationIVF treatment should not be postponed for patients with high basal FSH concentrations
Reproductive BioMedicine Online (2010) 21, 631 635 www.sciencedirect.com www.rbmonline.com SHORT COMMUNICATION IVF treatment should not be postponed for patients with high basal FSH concentrations Ettie
More informationAge and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome
British Journal of Obstetrics and Gynaecology January 1998, Vol. 105, pp. 107-1 12 Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome Khaldoun Sharif Lecturer, Manal
More informationIVF Performance of Women Who Have Fluctuating Early Follicular FSH Levels 1
CLINICAL ASSISTED REPRODUCTION IVF Performance of Women Who Have Fluctuating Early Follicular FSH Levels 1 A. LASS, 2,3 A. GERRARD, 2 N. ABUSHEIKHA, 2 F. AKAGBOSU, 2 and P. BRINSDEN 2 Submitted: April
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationPrognosticating ovarian reserve by the new ovarian response prediction index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Tak A et al. Int J Reprod Contracept Obstet Gynecol. 2018 Mar;7(3):1196-1200 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20180917
More informationFollicle-stimulating hormone/luteinizing hormone ratio as an independent predictor of response to controlled ovarian stimulation
Follicle-stimulating hormone/luteinizing hormone ratio as an independent predictor of response to controlled ovarian stimulation Aim: To determine whether a follicle-stimulating hormone (FSH)/luteinizing
More informationGn-RH Agonist Challenge Test for Predicting Ovarian Reserve in Short Protocol Cycles
J Obstet Gynecol lnd Vol. 54, No.1: January/February 2004 Pg 51-55 Gn-RH Agonist Challenge Test for Predicting Ovarian Reserve in Short Protocol Cycles Ocal Pelin, Cepni Ismail, Akbas Hande, Idil Mehmet,
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationInfertility Clinical Guideline
Infertility Clinical Guideline Ovarian Stimulation Guideline Purpose: To provide sufficient background regarding various ovarian stimulation protocols for In Vitro Fertilization cycles. Goal: To assist
More informationOptimizing the Management of the Poor Responder. Kaylen Silverberg, M.D. Texas Fertility Center Austin, Texas
Optimizing the Management of the Poor Responder Kaylen Silverberg, M.D. Texas Fertility Center Austin, Texas 2 Choices Donor Oocytes Break, eat, visit, enjoy weather Listen to lecture Argue, get grumpy,
More informationOvarian response in three consecutive in vitro fertilization cycles
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response in
More informationInternational Journal of Pharma and Bio Sciences ENDOCRINE MARKERS AND DECLINE IN REPRODUCTIVE POTENTIAL OF WOMEN ABSTRACT
Research Article Biochemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 ENDOCRINE MARKERS AND DECLINE IN REPRODUCTIVE POTENTIAL OF WOMEN BUSHRA FIZA *, 1, 2, RATI MATHUR 2, MAHEEP
More informationA luteal estradiol protocol for anticipated poor-responder patients may improve delivery rates
A luteal estradiol protocol for anticipated poor-responder patients may improve delivery rates Micah J. Hill, D.O., a Grant D. E. McWilliams, D.O., b Kathleen A. Miller, B.S., c Richard T. Scott, Jr, M.D.,
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More informationAccuracy of ovarian reserve tests
Human Reproduction vol. no. pp.-6, Accuracy of ovarian reserve tests BUlent Gülekli ' ', Yesim Bulbul, Ata Onvural, Kutsal Yorukoglu, Cemal Posaci, Namik Demir and Oktay Erten,, To whom correspondence
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationLUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi
LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency
More informationIs an Elevation in Basal Follicle-Stimulating Hormone Levels in Unexplained Infertility Predictive of Fecundity Regardless of Age?
Endocrine Journal 2001, 48 (6), 711-715 NOTE Is an Elevation in Basal Follicle-Stimulating Hormone Levels in Unexplained Infertility Predictive of Fecundity Regardless of Age? Koji KUGU*, MIKIo MOMOEDA*,
More informationJMSCR Vol 06 Issue 09 Page September 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i9.53 Role of Anti-Mullerian Hormone
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationVanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol
More informationOvarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy
Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy M.E. Coccia, F. Cammilli, L. Ginocchini, F. Borruto* and F. Rizzello Dept Gynaecology Perinatology and Human
More informationClinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
More informationCOMPARING AMH, AFC AND FSH FOR PREDICTING HIGH OVARIAN RESPONSE IN WOMEN UNDERGOING ANTAGONIST PROTOCOL
COMPARING AMH, AFC AND FSH FOR PREDICTING HIGH OVARIAN RESPONSE IN WOMEN UNDERGOING ANTAGONIST PROTOCOL Nguyen Xuan Hoi1, Nguyen Manh Ha2 1 National Obstetrics and Gynecology Hospital, 2Hanoi Medical Unviversity
More informationS.Fisher 1,3, A.Grin 2, A.Paltoo 2 and H.M.Shapiro 2
Human Reproduction Vol.20, No.1 pp. 84 88, 2005 Advance Access publication October 15, 2004 doi:10.1093/humrep/deh543 Falling estradiol levels as a result of intentional reduction in gonadotrophin dose
More informationRafael A. Cabrera, M.D., Laurel Stadtmauer, M.D., Ph.D., Jacob F. Mayer, Ph.D., William E. Gibbons, M.D., and Sergio Oehninger, M.D., Ph.D.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant
More informationBest practices of ASRM and ESHRE
Best practices of ASRM and ESHRE Late submission Cortina d Ampezzo, Italy 1-3 March 2012 A joint meeting between the American Society for Reproductive Medicine and the European Society of Human Reproduction
More informationIVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman
IVM in PCOS patients Michael Grynberg René Frydman Department of Obstetrics and Gynecology A. Beclere Hospital, Clamart, France Maribor, Slovenia, 27-28 February 2009 Introduction (1) IVM could be a major
More informationUtility of in vitro fertilization at diagnostic laparoscopy*
FERTILITY AND STERILITY Copyright" 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Utility of in vitro fertilization at diagnostic laparoscopy* Paul R. Gindoff, M.D.t Jerry L.
More informationENDOCRINE CHARACTERISTICS OF ART CYCLES
ENDOCRINE CHARACTERISTICS OF ART CYCLES DOÇ. DR. SEBİHA ÖZDEMİR ÖZKAN KOCAELI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, IVF UNIT 30.04.2014, ANTALYA INTRODUCTION The endocrine
More informationThe serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
Original Article Obstet Gynecol Sci 2018;61(2):242-246 https://doi.org/10.5468/ogs.2018.61.2.242 pissn 2287-8572 eissn 2287-8580 The serum estradiol/oocyte ratio in patients with breast cancer undergoing
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationIn Vitro Fertilization and Embryo Transfer
Acta Medica et Biologica Vol. 41, No.4, 171-176, 1993 The Influence of Low Ovarian Response on the Results of In Vitro Fertilization and Embryo Transfer Hirofumi HIRASAWA Department of Obstetrics and Gynecology,
More informationSummary
Summary 118 This thesis is focused on the background of elevated levels of FSH in the early follicular phase of women with regular menstrual cycles. In the introduction (chapter 1) we describe the characteristics
More informationPredictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older
Reprod Med Biol (2009) 8:145 149 DOI 10.1007/s12522-009-0023-z ORIGINAL ARTICLE Predictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older Akihisa
More informationThree-dimensional ultrasonographic ovarian measurements and in vitro fertilization outcome are related to age
FERTILITY AND STERILITY VOL. 79, NO. 1, JANUARY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Three-dimensional
More informationArticle Effect of cetrorelix dose on premature LH surge during ovarian stimulation
RBMOnline - Vol 16. No 6. 2008 772-777 Reproductive BioMedicine Online; www.rbmonline.com/article/3181 on web 18 April 2008 Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationEVALUATING THREE ALTERNATIVE PROTOCOLS FOR IMPROVING OVARIAN RESPOSE OF THE POOR RESPONDERS UNDERGOING ASSISSTED REPRODUCTIVE TECHNIQUES
EVALUATING THREE ALTERNATIVE PROTOCOLS FOR IMPROVING OVARIAN RESPOSE OF THE POOR RESPONDERS UNDERGOING ASSISSTED REPRODUCTIVE TECHNIQUES A Thesis Presented to The Faculty of Medicine, University of Alexandria,
More informationSignificance of basal follicle-stimulating hormone levels in women with one ovary in a program of in vitro fertilization*
FERTILITY AND STERILITY Copyright e 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Significance of basal follicle-stimulating hormone levels in women with one ovary in a program
More informationThe association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age
Reproductive BioMedicine Online (2010) 21, 757 761 www.sciencedirect.com www.rbmonline.com ARTICLE The association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age Jeff G
More informationIOF POI. hypergonadotropic hypogonadism primary ovarian insufficiency POI /premature ovarian failure POF. Van Kasteren. Coulam POI FSH E.
hypergonadotropic hypogonadism primary ovarian insufficiency POI /premature ovarian failure POF Coulam POI Turner Fragile X premutation FSHR NOBOX FOXL etc POI FSH miu/ml AMH AMH AMH FSH / Knauff POI IOF
More informationAntral follicle count in clinical practice: analyzing clinical relevance
CONTROVERSY I Antral follicle count in clinical practice: analyzing clinical relevance Albert Hsu, M.D., Margaret Arny, Ph.D., Alexander B. Knee, M.S., Carrie Bell, M.D., Elizabeth Cook, Ph.D., Amy L.
More informationPoor & Hyper responders: what is the best approach?
Poor & Hyper responders: what is the best approach? A. La Marca ObGyn Dept University of Modena and Reggio Emilia Italy Center for Reproductive Medicine University Hospital of Modena Italy Criteria used
More informationAntagonists in poor-responder patients
FERTILITY AND STERILITY VOL. 80, SUPPL. 1, JULY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Antagonists in poor-responder
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationSubject: Infertility Policy Effective Date: 01/07 Revision Date: 01/2018
Subject: Infertility Policy Effective Date: 01/07 Revision Date: 01/2018 DESCRIPTION Infertility is the condition of an individual who has been unable to conceive or produce conception during a period
More informationSuperovulation with human menopausal gonadotropins is associated with endometrial gland-stroma dyssynchrony*
aes FERTILITY AND STERILITY Vol. 61, No.4, April 1994 Copyright ee) 1994 The American Fertility Society Printed on acid-free paper in U. S. A. r I Superovulation with human menopausal gonadotropins is
More informationTreatment of Poor Responders
Treatment of Poor Responders Pathophysiology of Poor Responders Deficiency in systemic IGF 1 levels (Bahceci, 2007) Lower intra ovarian T levels Reduced FSH receptor expression (Cai, 2007) Bahceci, 2007,
More informationSTIMULATION AND OVULATION TRIGGERING
STIMULATION AND OVULATION TRIGGERING Professor IOANNIS E. MESSINIS MD, PhD (Aberdeen, UK), FRCOG (UK) Department of Obs/Gynae University of Thessaly Larissa, GREECE DISCLOSURE Nothing to disclose Learning
More informationThe Significance of Low Anti-Müllerian Hormone Levels in Young Women Undergoing in Vitro Fertilization
The Significance of Low Anti-Müllerian Hormone Levels in Young Women Undergoing in Vitro Fertilization Caitlin Haswell, M.D., Estil Strawn, Jr., M.D., Aniko Szabo, Ph.D., Joseph Davis, D.O., and Kate D.
More information(BMI)=18.0~24.9 kg/m 2 ;
33 10 Vol.33 No.10 2013 10 Oct. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.10.0672 E-mail: randc_journal@163.com - ( 400013) : () GnRH-a - () : IVF- ET 233 A (I~II 102 ) B (III~IV
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationAssisted reproductive technology
Assisted reproductive technology FERTILITY AND STERILITY Vol. 60, No.2, August 1993 Copyright 'c; 199:~ The American Fertility Society Printed on acid-free paper in U. S. A. Natural cycle in vitro fertilization-embryo
More informationOriginal Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer
Int J Clin Exp Med 2015;8(7):11327-11331 www.ijcem.com /ISSN:1940-5901/IJCEM0008838 Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and
More informationPremature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles
Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationResults and Discussion
The AMH and Inhibin B in serum and follicular fluid was a very good predictive marker for assessment of oocyte quantity but did not correlate with the maturity of the oocyte or fertilization or reproductive
More informationN. Shirazian, MD. Endocrinologist
N. Shirazian, MD Internist, Endocrinologist Inside the ovary Day 15-28: empty pyfollicle turns into corpus luteum (yellow body) Immature eggs Day 1-13: 13: egg developing inside the growing follicle Day
More informationHormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
More informationAnti-Mullerian hormone (AMH) as predictor of ovarian reserve
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Shembekar CA et al. Int J Reprod Contracept Obstet Gynecol. 2017 Sep;6(9):4006-4010 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20174053
More informationI. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
More informationA multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of
A multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of Endometrioma and deep infiltrating endometriosis Professor C. Chapron and the Group
More informationREstradiol and Antagonist Pretreatment Prior to Microdose Leuprolide in in Vitro Fertilization
REstradiol and Antagonist Pretreatment Prior to Microdose Leuprolide in in Vitro Fertilization Does It Improve IVF Outcomes in Poor Responders as Compared to Oral Contraceptive Pill? FTThe Journal of Reproductive
More informationAntral follicle count as a predictor of ovarian response
Original article Antral follicle count as a predictor of ovarian response N. Lonegro a, N. Napoli a,*, R. Pesce b and C. Chacón a a Imaging Department, Hospital Italiano de Buenos Aires, Ciudad Autónoma
More information2017 United HealthCare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationMilan Reljič, Ph.D., Veljko Vlaisavljević, Ph.D., Vida Gavrić, M.Sc., Borut Kovačič, Ph.D.,
FERTILITY AND STERILITY VOL. 75, NO. 3, MARCH 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Value of the serum estradiol
More informationEvaluation of ovarian response prediction according to age and serum AMH levels in IVF cycles: a retrospective analysis
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Pillai SM et al. Int J Reprod Contracept Obstet Gynecol. 2017 Aug;6(8):3306-3310 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20173190
More informationPrognostic factors of ovarian response and IVF outcome in patients with deep infiltrating endometriosis Claire GAUCHE-CAZALIS, Chadi YAZBECK
Prognostic factors of ovarian response and IVF outcome in patients with deep infiltrating endometriosis Claire GAUCHE-CAZALIS, Chadi YAZBECK Obstetrics Gynecology and Reproductive Medicine Department Bichat
More informationOvarian age-based stimulation of young women with diminished ovarian reserve results in excellent pregnancy rates with in vitro fertilization
Ovarian age-based stimulation of young women with diminished ovarian reserve results in excellent pregnancy rates with in vitro fertilization Norbert Gleicher, M.D., and David Barad, M.D. Center for Human
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationLOW COST PROTOCOL VERSUS SHORT PROTOCOL FOR CONTROLLED OVARIAN STIMULATION IN ICSI TRIALS
LOW COST PROTOCOL VERSUS SHORT PROTOCOL FOR CONTROLLED OVARIAN STIMULATION IN ICSI TRIALS Salem H. H. '; Nassar A. M.,&l ; Askalany N. A. ', Kassem K. 1&4 Department of Obstetrics and Gynecology Al Azhar
More informationObesity does not impact implantation rates or pregnancy outcome in women attempting conception through oocyte donation
IN VITRO FERTILIZATION Obesity does not impact implantation rates or pregnancy outcome in women attempting conception through oocyte donation Allison Styne-Gross, M.D., a Karen Elkind-Hirsch, Ph.D., b
More informationLUTEINIZED UNRUPTURED FOLLICLE SYNDROME: A SUBTLE CAUSE OF INFERTILITY*
FERTILITY AND STERILITY Copyright c 1978 The American Fertility Society Vol. 29, No.3, March 1978 Printed in U.S.A. LUTEINIZED UNRUPTURED FOLLICLE SYNDROME: A SUBTLE CAUSE OF INFERTILITY* JAROSLA V MARIK,
More informationIvf day 6 estradiol level
Ivf day 6 estradiol level Search It is also important to measure the estradiol on day 3. Day 2 is fine. The reason its day 3 is 15-20 years ago, the IVF medications were always started on day 3. Day 3
More informationN.A.Bersinger 1, A.Brandenberger, E.Berger, C.K.Baumann and M.H.Birkhäuser
Human Reproduction vol.13 no.7 pp.1962 1967, 1998 Serum pregnancy-specific β 1 -glycoprotein before embryo transfer is related to endometrial thickness and to outcome prognosis in women undergoing in-vitro
More informationInfertility: A Generalist s Perspective
Infertility: A Generalist s Perspective Learning Objectives Fertility and Lifestyle: Patient education Describe the basic infertility workup Basic treatment strategies unexplained Heather Huddleston, MD
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationUtility of Estradiol as a Predictive Marker of Ovarian Hyper Stimulation Syndrome
Research Article imedpub Journals http://www.imedpub.com/ Annals of Clinical and Laboratory Research DOI: 10.21767/2386-5180.1000167 Utility of Estradiol as a Predictive Marker of Ovarian Hyper Stimulation
More informationComparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization
Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization Peter Kovacs, M.D., a Timea Kovats, M.D., a Artur Bernard,
More information